Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from Vor Biopharma ( (VOR) ).
Vor Biopharma has appointed Erez Kalir, a seasoned investor and entrepreneur with deep experience in life sciences and technology, to its Board of Directors. This strategic appointment aligns with the company’s vision to advance its clinical programs and drive innovation in cancer treatment, potentially strengthening its market position and stakeholder confidence.
More about Vor Biopharma
Vor Bio is a clinical-stage cell and genome engineering company focused on developing advanced treatments for blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant.
YTD Price Performance: 48.21%
Average Trading Volume: 744,644
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $119.5M
See more data about VOR stock on TipRanks’ Stock Analysis page.
